ArticleTissue engineering. Part C, Methods2020
Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Article in Tissue engineering. Part C, Methods, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 80 citations in OpenAlex.
- Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Organ-on-chip (OoC) and nano-biomaterials: next generation of precision oral and dental healthcare research.Journal of nanobiotechnology · 2026Review
- Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025Review
- Human iPSC-Based in Vitro Cardiovascular Tissue Models for Drug Screening Applications.Current cardiology reports · 2025Review
- Novel 2D/3D Hybrid Organoid System for High-Throughput Drug Screening in iPSC Cardiomyocytes.Therapeutics · 2025Article
- Cancer-on-a-chip for precision cancer medicine.Lab on a chip · 2025Review
- Cardiac Tissue Engineering for Translational Cardiology: From In Vitro Models to Regenerative Therapies.Bioengineering (Basel, Switzerland) · 2025Review
- A Biomimetic Human Multi-Cellular In Vitro Model of the Blood-Brain Barrier.International journal of molecular sciences · 2025Article
- RCAN1.4 regulates tumor cell engraftment and invasion in a thyroid cancer to lung metastasis-on-a-chip microphysiological system.Biofabrication · 2024Article
- Extracellular matrix-inspired biomaterials for wound healing.Molecular biology reports · 2024Review
- Advances in cardiac tissue engineering and heart-on-a-chip.Journal of biomedical materials research. Part A · 2024Review
- Stem cell modeling of nervous system tumors.Disease models & mechanisms · 2024Review
- Review: Human stem cell-based 3D in vitro angiogenesis models for preclinical drug screening applications.Molecular biology reports · 2024Review
- Scaffold-based 3D cell culture models in cancer research.Journal of biomedical science · 2024Review
- A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications.Biomaterials · 2024Review
- Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.Cell biology and toxicology · 2023Review
- Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings:JACC. CardioOncology · 2023Review
- A microfluidic organ-on-a-chip: into the next decade of bone tissue engineering applied in dentistry.Future science OA · 2023Review
- Mitigating neutrophil trafficking and cardiotoxicity with DS-IkL in a microphysiological system of a cytokine storm.Lab on a chip · 2023Article
- Emerging trends in organ-on-a-chip systems for drug screening.Acta pharmaceutica Sinica. B · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer remains a leading health threat in the United States, and cardiovascular drug toxicity is a primary cause to eliminate a drug from FDA approval. As a result, the demand to develop new anticancer drugs without cardiovascular toxicity is high. Human induced pluripotent stem (iPS) cell-derived tissue chips provide potentially a cost-effective preclinical drug testing platform, including potential avenues for personalized medicine. We have developed a three-dimensional microfluidic device that simultaneously cultures tumor cell spheroids with iPS-derived cardiomyocytes (iPS-CMs) and iPS-derived endothelial cells (iPS-EC). The iPS-derived cells include a GCaMP6 fluorescence reporter to allow real-time imaging to monitor intracellular calcium transients. The multiple-chambered tissue chip features electrodes for pacing of the cardiac tissue to assess cardiomyocyte function such as the maximum capture rate and conduction velocity. We measured the inhibition concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.